Nocturnal Sleep Signature for Diagnosing Idiopathic Hypersomnia

Who could benefit from this research

What this research studies

This project aims to create and validate an objective biomarker signature from overnight sleep data to accurately diagnose idiopathic hypersomnia in teens. Researchers will combine neurophysiological data, sleep patterns, and statistical models to distinguish IH from other sleep disorders. The work builds on prior findings that IH shows distinctive nocturnal sleep features and may improve how patients are diagnosed and enrolled in future trials. Participation would involve noninvasive sleep monitoring and data collection during scheduled study periods. If successful, this could lead to earlier and more precise diagnoses and better-targeted treatments for affected youth.

Why it matters

Where this research is happening

• Boston Children's Hospital
  Boston, United States Active

Researchers

• Principal investigator: Maski, Kiran Prasad — Boston Children's Hospital
• Study coordinator: Maski, Kiran Prasad

Related research

Other NIH-funded projects on the same topics.

• Creating a new way to diagnose idiopathic hypersomnia using sleep patterns

  This study is looking to find a new way to diagnose idiopathic hypersomnia, a condition that makes you feel really sleepy during the day, by identifying specific biological markers in your sleep patterns, so that people can get the right help more easily.

  NIH research Boston Children's Hospital · Boston, United States · NIH-11083750

• Long-term test of TAK-360 in people with narcolepsy or idiopathic hypersomnia

  This study tests TAK-360 over an extended period to see if it is tolerable for people with narcolepsy type 1, narcolepsy type 2, or idiopathic hypersomnia who completed an earlier TAK-360 trial.

  Recruiting at 33 sites Phase 2/3 Takeda · Chula Vista, California and 32 other locations · NCT07646678

• Expanded-dosing Xywav vs placebo in narcolepsy and IH

  This study tests whether expanded nightly dosing of Xywav helps adults with narcolepsy or idiopathic hypersomnia, compared with placebo.

  Recruiting at 15 sites Phase 3 Jazz Pharmaceuticals · Birmingham, Alabama and 14 other locations · NCT07625280

• Phase 3 HBS-301 for idiopathic hypersomnia

  This trial will test whether the oral medicine HBS-301 helps adults with idiopathic hypersomnia reduce daytime sleepiness, sleep inertia, and fatigue.

  Recruiting at 42 sites Phase 3 Harmony Biosciences Management, Inc. · Birmingham, Alabama and 41 other locations · NCT07500090

• Long-term ORX750 treatment for people with narcolepsy or idiopathic hypersomnia

  This open-label extension will try continued ORX750 treatment in people with narcolepsy or idiopathic hypersomnia who completed the earlier ORX750 parent study.

  Recruiting at 24 sites Phase 2 Centessa Pharmaceuticals (UK) Limited · Auburn, Alabama and 23 other locations · NCT07096674

• Diet changes to reduce sleepiness in narcolepsy and idiopathic hypersomnia

  This project will try whether a 12-week whole-food ketogenic diet versus an isocaloric standard whole-food diet reduces daytime sleepiness and improves quality of life in adults with narcolepsy or idiopathic hypersomnia.

  Recruiting University of Sydney · Macquarie Park, New South Wales · NCT07006233

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.